Related Experiment Video

Updated: Oct 3, 2026

Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format
12:39

Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format

Published on: June 24, 2011

Susceptibility of streptomycin-resistant Mycobacterium tuberculosis strains to amikacin

S E Hoffner1, G Källenius

  • 1Department of Bacteriology, National Bacteriological Laboratory, Stockholm, Sweden.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|April 1, 1988
PubMed

Insights

Amikacin is a viable alternative for treating streptomycin-resistant tuberculosis. Most Mycobacterium tuberculosis strains resistant to streptomycin remained susceptible to amikacin, indicating its therapeutic potential.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Tuberculosis (TB) remains a global health challenge.
  • Drug resistance in Mycobacterium tuberculosis complicates treatment regimens.
  • Streptomycin has been a cornerstone in TB treatment, but resistance is a growing concern.

Purpose of the Study:

  • To evaluate the in vitro susceptibility of Mycobacterium tuberculosis strains to amikacin compared to streptomycin.
  • To determine the prevalence of streptomycin resistance in a Swedish isolate collection.
  • To assess amikacin as a potential alternative for streptomycin-resistant TB cases.

Main Methods:

  • Susceptibility testing of 585 Mycobacterium tuberculosis isolates.
  • Comparison of in vitro activity between amikacin and streptomycin.
  • Analysis of resistance patterns in relation to patient demographics.

Main Results:

  • A total of 4.6% of isolates exhibited resistance to streptomycin.
  • All but one streptomycin-resistant isolate were susceptible to amikacin.
  • No streptomycin-susceptible isolates showed resistance to amikacin.

Conclusions:

  • Amikacin demonstrates significant in vitro activity against streptomycin-resistant Mycobacterium tuberculosis.
  • Amikacin represents a promising alternative therapeutic option for patients with streptomycin-resistant TB.
  • Further clinical studies are warranted to confirm amikacin's efficacy in treating resistant TB.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Amikacin Protection Assay for Quantification and Visualization of Escherichia coli Cell Invasion09:22

Amikacin Protection Assay for Quantification and Visualization of Escherichia coli Cell Invasion

Published on: July 3, 2026

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...